Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
28.60
-0.07 (-0.24%)
At close: May 14, 2026, 4:00 PM EDT
28.60
0.00 (0.00%)
After-hours: May 14, 2026, 4:16 PM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
The 12 analysts that cover Legend Biotech stock have a consensus rating of "Strong Buy" and an average price target of $62.08, which forecasts a 117.06% increase in the stock price over the next year. The lowest target is $29 and the highest is $80.
Price Target: $62.08 (+117.06%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 8 | 8 | 8 | 7 |
| Hold | 1 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 14 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $21 → $29 | Hold | Maintains | $21 → $29 | +1.40% | May 13, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $49 → $48 | Buy | Maintains | $49 → $48 | +67.83% | May 13, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $62 → $64 | Buy | Maintains | $62 → $64 | +123.78% | May 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +74.83% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +74.83% | Apr 15, 2026 |
Financial Forecast
Revenue This Year
1.47B
from 1.03B
Increased by 42.68%
Revenue Next Year
1.91B
from 1.47B
Increased by 30.31%
EPS This Year
0.20
from -1.62
EPS Next Year
1.04
from 0.20
Increased by 410.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.6B | 2.2B | ||||||
| Avg | 1.5B | 1.9B | ||||||
| Low | 1.3B | 1.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 58.4% | 51.6% | ||||||
| Avg | 42.7% | 30.3% | ||||||
| Low | 24.5% | 2.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.70 | 1.92 | |
| Avg | 0.20 | 1.04 | |
| Low | -0.20 | 0.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 846.0% | |
| Avg | - | 410.9% | |
| Low | - | -44.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.